These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33103202)

  • 1. Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.
    Gill CM; Asempa TE; Nicolau DP
    J Antimicrob Chemother; 2021 Jan; 76(1):184-188. PubMed ID: 33103202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2022 Sep; 77(10):2622-2631. PubMed ID: 35325165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2023 Mar; 78(3):636-645. PubMed ID: 36626311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
    Gill CM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Lasko MJ; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
    Ruiz VH; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae.
    Sabet M; Tarazi Z; Nolan T; Parkinson J; Rubio-Aparicio D; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
    Shortridge D; Carvalhaes C; Deshpande L; Castanheira M
    J Antimicrob Chemother; 2021 Sep; 76(10):2600-2605. PubMed ID: 34302173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems.
    Abdelraouf K; Reyes S; Nicolau DP
    J Antimicrob Chemother; 2021 Feb; 76(3):684-691. PubMed ID: 33179050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
    Lasko MJ; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
    Castanheira M; Rhomberg PR; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
    Bhowmick T; Weinstein MP
    Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo exposure-response relationship of meropenem against metallo-β-lactamase-harbouring Pseudomonas aeruginosa: an assessment using MICs from conventional and zinc-limited broth.
    Kois AK; Nicolau DP; Asempa TE
    J Antimicrob Chemother; 2022 Jun; 77(7):1938-1948. PubMed ID: 35488847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an
    Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.